A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Emmanuel Bachy,Matthew J. Maurer,Thomas M. Habermann,Bénédicte Gelas-Dore,Delphine Maucort-Boulch,Delphine Maucort-Boulch,Jane Estell,Jane Estell,Eric Van Den Neste,Reda Bouabdallah,Emmanuel Gyan,Andrew L. Feldman,Joan Bargay,Alain Delmer,Susan L. Slager,Maria Gomes da Silva,Olivier Fitoussi,David Belada,Hervé Maisonneuve,Tanin Intragumtornchai,Stephen M. Ansell,Thierry Lamy,Peggy Dartigues,Brian K. Link,John F. Seymour,James R. Cerhan,Gilles Salles +26 more
Reads0
Chats0
TLDR
The PRIMA-PI is a novel and easy-to-compute prognostic index for patients initially treated with immunochemotherapy and could serve as a basis for building more sophisticated and integrated biomolecular scores.About:
This article is published in Blood.The article was published on 2018-07-05 and is currently open access. It has received 131 citations till now. The article focuses on the topics: International Prognostic Index & Follicular lymphoma.read more
Citations
More filters
Journal ArticleDOI
Follicular lymphoma: 2020 update on diagnosis and management.
TL;DR: Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells that is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly.
Journal ArticleDOI
Follicular lymphoma: Nature Reviews. Disease Primers
Antonino Carbone,Sandrine Roulland,Annunziata Gloghini,Anas Younes,Gottfried von Keudell,Armando López-Guillermo,Jude Fitzgibbon +6 more
Journal ArticleDOI
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration
Joshua W.D. Tobin,Joshua W.D. Tobin,Colm Keane,Colm Keane,Jay Gunawardana,Peter Mollee,Simone Birch,Thanh Hoang,Justina Lee,Li Li,Li Huang,Valentine Murigneux,J. Lynn Fink,Nicholas Matigian,Frank Vari,Santiyagu M. Savarimuthu Francis,Robert Kridel,Oliver Weigert,Sarah Haebe,Vindi Jurinovic,Wolfram Klapper,Christian Steidl,Laurie H. Sehn,Soi Cheng Law,Michelle N. Wykes,Maher K. Gandhi,Maher K. Gandhi +26 more
TL;DR: Assessment of immune-infiltration by PD-L2 expression is a promising tool with which to help identify patients who are at risk for POD24, and degree of immune infiltration is capturing aspects of FL biology distinct from its mutational profile.
Journal ArticleDOI
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy
Sandra Lockmer,Sandra Lockmer,Weicheng Ren,Marianne Brodtkorb,Bjørn Østenstad,Björn E. Wahlin,Björn E. Wahlin,Qiang Pan-Hammarström,Eva Kimby +8 more
TL;DR: The prognostic value of the m7‐FLIPI clinicogenetic model seems dependent on therapeutic regimen, and no difference in time to treatment failure (TTF), nor overall survival (OS) was found between the m8‐FLipI risk groups.
Journal ArticleDOI
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
TL;DR: In this article , the authors performed a pooled analysis of 13 randomized clinical trials of patients with follicular lymphoma (FL) in the pre- and postrituximab eras to identify clinical factors that predict POD24.
References
More filters
Journal Article
R: A language and environment for statistical computing.
TL;DR: Copyright (©) 1999–2012 R Foundation for Statistical Computing; permission is granted to make and distribute verbatim copies of this manual provided the copyright notice and permission notice are preserved on all copies.
Book
Modeling Survival Data: Extending the Cox Model
TL;DR: A Cox Model-based approach was used to estimate the Survival and Hazard Functions and the results confirmed the need for further investigation into the role of natural disasters in shaping survival rates.
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
International staging system for multiple myeloma.
Philip R. Greipp,Jesús F. San Miguel,Brian G.M. Durie,John Crowley,Bart Barlogie,Joan Bladé,Mario Boccadoro,J. Anthony Child,Hervé Avet-Loiseau,Robert A. Kyle,Juan J. Lahuerta,Heinz Ludwig,Gareth J. Morgan,R. L. Powles,Kazuyuki Shimizu,Chaim Shustik,Pieter Sonneveld,Patrizia Tosi,Ingemar Turesson,Jan Westin +19 more
TL;DR: The new International Staging System (ISS) is simple, based on easy to use variables (Sbeta2M and serum albumin), and recommended for early adoption and widespread use.
Journal ArticleDOI
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
TL;DR: Net reclassification improvement offers a simple intuitive way of quantifying improvement offered by new markers and has been gaining popularity among researchers, however, several aspects of the NRI have not been studied in sufficient detail.
Related Papers (5)
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico,Monica Bellei,Luigi Marcheselli,Stefano Luminari,Armando López-Guillermo,Umberto Vitolo,Barbara Pro,Stefano Pileri,Alessandro Pulsoni,Pierre Soubeyran,Sergio Cortelazzo,Giovanni Martinelli,Maurizio Martelli,Luigi Rigacci,Luca Arcaini,Francesco Di Raimondo,Francesco Merli,Elena Sabattini,Peter McLaughlin,Philippe Solal-Celigny +19 more
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles,John F. Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Reda Bouabdallah,John Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Myriam Mendila,Bertrand Coiffier,Hervé Tilly +29 more